Atlas Trials

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Clinical trial NCT02576496 · COMPLETED

Trial details

NCT number
NCT02576496
Sponsor
Mundipharma Research Limited
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hematological MalignanciesMultiple MyelomaHodgkin's LymphomaCutaneous T Cell Lymphoma
Start date
2016-04-14
Primary completion
2023-05-30
Enrollment
106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.